539 related articles for article (PubMed ID: 30628699)
1. Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
Hori S; Miyake M; Tatsumi Y; Morizawa Y; Nakai Y; Onishi S; Onishi K; Iida K; Gotoh D; Itami Y; Tanaka N; Fujimoto K
Oncol Rep; 2019 Mar; 41(3):1863-1874. PubMed ID: 30628699
[TBL] [Abstract][Full Text] [Related]
2. Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model.
Hori S; Miyake M; Tatsumi Y; Onishi S; Morizawa Y; Nakai Y; Tanaka N; Fujimoto K
PLoS One; 2017; 12(4):e0175494. PubMed ID: 28406993
[TBL] [Abstract][Full Text] [Related]
3. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
[TBL] [Abstract][Full Text] [Related]
4. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
5. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
[TBL] [Abstract][Full Text] [Related]
6. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
[TBL] [Abstract][Full Text] [Related]
7. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
Böhle A; Bock PR
Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
[TBL] [Abstract][Full Text] [Related]
8. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
9. Contemporary intravesical treatment options for urothelial carcinoma of the bladder.
Brassell SA; Kamat AM
J Natl Compr Canc Netw; 2006 Nov; 4(10):1027-36. PubMed ID: 17112451
[TBL] [Abstract][Full Text] [Related]
10. Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.
Saluja M; Gilling P
Int J Urol; 2018 Jan; 25(1):18-24. PubMed ID: 28741703
[TBL] [Abstract][Full Text] [Related]
11. [Effect of intravesical bacillus Calmette-Guérin on N-butyl-N-(4-hydroxybutyl)-nitrosamine induced urinary bladder carcinogenesis in rats].
Yanagisawa T; Suzuki T; Kudoh T; Oh SC
Nihon Hinyokika Gakkai Zasshi; 1994 Jun; 85(6):945-52. PubMed ID: 8065076
[TBL] [Abstract][Full Text] [Related]
12. [Histological study on intravesical instillation of Bacillus Calmette Guerin (BCG) and adriamycin for BBN-induced bladder tumor in rats].
Tanaka S; Kudoh S; Mollik AU; Kudoh T; Kogawa T; Suzuki T
Nihon Hinyokika Gakkai Zasshi; 1992 Mar; 83(3):368-73. PubMed ID: 1564838
[TBL] [Abstract][Full Text] [Related]
13. Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial.
Svatek RS; Zhao XR; Morales EE; Jha MK; Tseng TY; Hugen CM; Hurez V; Hernandez J; Curiel TJ
Clin Cancer Res; 2015 Jan; 21(2):303-11. PubMed ID: 25424854
[TBL] [Abstract][Full Text] [Related]
14. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Di Stasi SM; Giannantoni A; Giurioli A; Valenti M; Zampa G; Storti L; Attisani F; De Carolis A; Capelli G; Vespasiani G; Stephen RL
Lancet Oncol; 2006 Jan; 7(1):43-51. PubMed ID: 16389183
[TBL] [Abstract][Full Text] [Related]
15. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer.
Chen CH; Yang HJ; Shun CT; Huang CY; Huang KH; Yu HJ; Pu YS
Urol Oncol; 2012; 30(4):421-7. PubMed ID: 20870427
[TBL] [Abstract][Full Text] [Related]
16. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
Chang SG; Lee SJ; Huh JS; Lee JH
Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
[TBL] [Abstract][Full Text] [Related]
17. Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder.
Sekine H; Ohya K; Kojima SI; Igarashi K; Fukui I
Int J Urol; 2001 Sep; 8(9):483-6. PubMed ID: 11683967
[TBL] [Abstract][Full Text] [Related]
18. Patient Compliance With Maintenance Intravesical Therapy for Nonmuscle Invasive Bladder Cancer.
Tapiero S; Helfand A; Kedar D; Yossepowitch O; Nadu A; Baniel J; Lifshitz D; Margel D
Urology; 2018 Aug; 118():107-113. PubMed ID: 29792974
[TBL] [Abstract][Full Text] [Related]
19. Effects of photodynamic therapy in combination with intravesical drugs in a murine bladder tumor model.
Cho YH; Straight RC; Smith JA
J Urol; 1992 Mar; 147(3):743-6. PubMed ID: 1538475
[TBL] [Abstract][Full Text] [Related]
20. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
Evans CP
Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
[No Abstract] [Full Text] [Related]
[Next] [New Search]
